Guidelines  ||| S:0 E:11 ||| NNS
for  ||| S:11 E:15 ||| IN
multimodality  ||| S:15 E:29 ||| JJ
radiological  ||| S:29 E:42 ||| JJ
staging  ||| S:42 E:50 ||| NN
of  ||| S:50 E:53 ||| IN
lung  ||| S:53 E:58 ||| NN
cancer  ||| S:58 E:65 ||| NN
Lung  ||| S:65 E:70 ||| NNP
cancer  ||| S:70 E:77 ||| NN
is  ||| S:77 E:80 ||| VBZ
among  ||| S:80 E:86 ||| IN
the  ||| S:86 E:90 ||| DT
most  ||| S:90 E:95 ||| RBS
common  ||| S:95 E:102 ||| JJ
type  ||| S:102 E:107 ||| NN
of  ||| S:107 E:110 ||| IN
cancers  ||| S:110 E:118 ||| NNS
and  ||| S:118 E:122 ||| CC
is  ||| S:122 E:125 ||| VBZ
a  ||| S:125 E:127 ||| DT
leading  ||| S:127 E:135 ||| JJ
cause  ||| S:135 E:141 ||| NN
of  ||| S:141 E:144 ||| IN
cancer-related  ||| S:144 E:159 ||| JJ
deaths  ||| S:159 E:166 ||| NNS
with  ||| S:166 E:171 ||| IN
smoking  ||| S:171 E:179 ||| NN
representing  ||| S:179 E:192 ||| VBG
the  ||| S:192 E:196 ||| DT
leading  ||| S:196 E:204 ||| JJ
risk  ||| S:204 E:209 ||| NN
factor ||| S:209 E:215 ||| NN
.  ||| S:215 E:217 ||| .
It  ||| S:217 E:220 ||| PRP
is  ||| S:220 E:223 ||| VBZ
classified  ||| S:223 E:234 ||| VBN
into  ||| S:234 E:239 ||| IN
non-small  ||| S:239 E:249 ||| JJ
cell  ||| S:249 E:254 ||| NN
lung  ||| S:254 E:259 ||| NN
cancer  ||| S:259 E:266 ||| NN
( ||| S:266 E:267 ||| -LRB-
NSCLC ||| S:267 E:272 ||| NNP
)  ||| S:272 E:274 ||| -RRB-
representing  ||| S:274 E:287 ||| VBG
70-80 ||| S:287 E:292 ||| CD
%  ||| S:292 E:294 ||| NN
of  ||| S:294 E:297 ||| IN
cases  ||| S:297 E:303 ||| NNS
and  ||| S:303 E:307 ||| CC
small  ||| S:307 E:313 ||| JJ
cell  ||| S:313 E:318 ||| NN
lung  ||| S:318 E:323 ||| NN
cancer  ||| S:323 E:330 ||| NN
( ||| S:330 E:331 ||| -LRB-
SCLC ||| S:331 E:335 ||| NNP
)  ||| S:335 E:337 ||| -RRB-
which  ||| S:337 E:343 ||| WDT
has  ||| S:343 E:347 ||| VBZ
neuroendocrine  ||| S:347 E:362 ||| JJ
properties  ||| S:362 E:373 ||| NNS
with  ||| S:373 E:378 ||| IN
poor  ||| S:378 E:383 ||| JJ
outcome ||| S:383 E:390 ||| NN
.  ||| S:390 E:392 ||| .
Staging  ||| S:392 E:400 ||| VBG
of  ||| S:400 E:403 ||| IN
NSCLC  ||| S:403 E:409 ||| NNP
is  ||| S:409 E:412 ||| VBZ
based  ||| S:412 E:418 ||| VBN
on  ||| S:418 E:421 ||| IN
the  ||| S:421 E:425 ||| DT
TNM  ||| S:425 E:429 ||| NNP
classification  ||| S:429 E:444 ||| NN
system  ||| S:444 E:451 ||| NN
while  ||| S:451 E:457 ||| IN
SCLC  ||| S:457 E:462 ||| NNP
was  ||| S:462 E:466 ||| VBD
usually  ||| S:466 E:474 ||| RB
classified  ||| S:474 E:485 ||| VBN
into  ||| S:485 E:490 ||| IN
limited  ||| S:490 E:498 ||| JJ
and  ||| S:498 E:502 ||| CC
extensive  ||| S:502 E:512 ||| JJ
disease ||| S:512 E:519 ||| NN
,  ||| S:519 E:521 ||| ,
though  ||| S:521 E:528 ||| IN
the  ||| S:528 E:532 ||| DT
use  ||| S:532 E:536 ||| NN
of  ||| S:536 E:539 ||| IN
TNM  ||| S:539 E:543 ||| NNP
staging  ||| S:543 E:551 ||| NN
system  ||| S:551 E:558 ||| NN
for  ||| S:558 E:562 ||| IN
SCLC  ||| S:562 E:567 ||| NNP
is  ||| S:567 E:570 ||| VBZ
recommended ||| S:570 E:581 ||| VBN
.  ||| S:581 E:583 ||| .
Imaging  ||| S:583 E:591 ||| JJ
studies  ||| S:591 E:599 ||| NNS
are  ||| S:599 E:603 ||| VBP
used  ||| S:603 E:608 ||| VBN
to  ||| S:608 E:611 ||| TO
determine  ||| S:611 E:621 ||| VB
the  ||| S:621 E:625 ||| DT
pre-operative  ||| S:625 E:639 ||| JJ
staging  ||| S:639 E:647 ||| NN
of  ||| S:647 E:650 ||| IN
lung  ||| S:650 E:655 ||| NN
cancer ||| S:655 E:661 ||| NN
.  ||| S:661 E:663 ||| .
Accurate  ||| S:663 E:672 ||| JJ
radiological  ||| S:672 E:685 ||| JJ
staging  ||| S:685 E:693 ||| NN
is  ||| S:693 E:696 ||| VBZ
essential  ||| S:696 E:706 ||| JJ
to  ||| S:706 E:709 ||| TO
determine  ||| S:709 E:719 ||| VB
tumor  ||| S:719 E:725 ||| NN
resectability  ||| S:725 E:739 ||| NN
as  ||| S:739 E:742 ||| IN
well  ||| S:742 E:747 ||| RB
as  ||| S:747 E:750 ||| RB
to  ||| S:750 E:753 ||| TO
avoid  ||| S:753 E:759 ||| VB
futile  ||| S:759 E:766 ||| JJ
surgeries  ||| S:766 E:776 ||| NN
and  ||| S:776 E:780 ||| CC
to  ||| S:780 E:783 ||| TO
assess  ||| S:783 E:790 ||| VB
patient ||| S:790 E:797 ||| NN
's  ||| S:797 E:800 ||| POS
outcome ||| S:800 E:807 ||| NN
.  ||| S:807 E:809 ||| .
Moreover ||| S:809 E:817 ||| RB
,  ||| S:817 E:819 ||| ,
radiological  ||| S:819 E:832 ||| JJ
examinations  ||| S:832 E:845 ||| NNS
are  ||| S:845 E:849 ||| VBP
used  ||| S:849 E:854 ||| VBN
for  ||| S:854 E:858 ||| IN
the  ||| S:858 E:862 ||| DT
evaluation  ||| S:862 E:873 ||| NN
of  ||| S:873 E:876 ||| IN
tumor  ||| S:876 E:882 ||| NN
response  ||| S:882 E:891 ||| NN
to  ||| S:891 E:894 ||| TO
treatment ||| S:894 E:903 ||| NN
.  ||| S:903 E:905 ||| .
This  ||| S:905 E:910 ||| DT
manuscript  ||| S:910 E:921 ||| NN
will  ||| S:921 E:926 ||| MD
review  ||| S:926 E:933 ||| VB
the  ||| S:933 E:937 ||| DT
utilization  ||| S:937 E:949 ||| NN
of  ||| S:949 E:952 ||| IN
imaging  ||| S:952 E:960 ||| JJ
studies  ||| S:960 E:968 ||| NNS
in  ||| S:968 E:971 ||| IN
the  ||| S:971 E:975 ||| DT
management  ||| S:975 E:986 ||| NN
of  ||| S:986 E:989 ||| IN
lung  ||| S:989 E:994 ||| NN
cancer  ||| S:994 E:1001 ||| NN
based  ||| S:1001 E:1007 ||| VBN
on  ||| S:1007 E:1010 ||| IN
the  ||| S:1010 E:1014 ||| DT
most  ||| S:1014 E:1019 ||| RBS
recent  ||| S:1019 E:1026 ||| JJ
guidelines  ||| S:1026 E:1037 ||| NNS
by  ||| S:1037 E:1040 ||| IN
the  ||| S:1040 E:1044 ||| DT
National  ||| S:1044 E:1053 ||| NNP
Comprehensive  ||| S:1053 E:1067 ||| NNP
Cancer  ||| S:1067 E:1074 ||| NNP
Network  ||| S:1074 E:1082 ||| NNP
( ||| S:1082 E:1083 ||| -LRB-
NCCN ||| S:1083 E:1087 ||| NNP
) ||| S:1087 E:1088 ||| -RRB-
.  ||| S:1088 E:1090 ||| .
